Home › RLT targets by cancer › Endometrial Cancer
Radioligand therapy · Endometrial Cancer

Radioligand Therapy Targets in Endometrial Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in endometrial cancer (including uterine endometrial carcinoma). 4,333 show detectable protein staining. Established and emerging radioligand targets expressed in endometrial cancer include EPCAM, HER3 (ERBB3), B7-H3 (CD276) and ITGAV. Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own endometrial cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank endometrial cancer targets free

Established and emerging radioligand targets in endometrial cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in endometrial cancer:

TargetIHC in endometrial cancer% positiveInternalizes
EPCAMHigh (0.97)100%—
HER3 (ERBB3)High (0.82)100%yes
B7-H3 (CD276)High (0.77)100%—
ITGAVHigh (0.70)100%—
c-MET (MET)High (0.67)100%yes
STEAP2High (0.64)100%—
EGFRMedium (0.48)73%yes
Nectin-4 (NECTIN4)Medium (0.47)90%no
SSTR2Medium (0.33)73%yes
CEA (CEACAM5)Medium (0.30)56%—
TMEFF2Medium (0.28)58%—
Mesothelin (MSLN)Medium (0.25)42%yes
ITGB6Medium (0.24)46%—
FAPMedium (0.20)40%yes
PSMA (FOLH1)Low (0.18)27%yes
DLK1Low (0.15)36%—
HER2 (ERBB2)Low (0.14)33%yes
TROP2 (TACSTD2)Low (0.11)33%uncertain

Top cell-surface targets for endometrial cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in endometrial cancer% positiveInternalizesClinical stage
1S1PR1
sphingosine-1-phosphate receptor 1
High (0.79)100%yesFDA-Approved
2IGF1R
insulin like growth factor 1 receptor
High (0.91)100%yesFDA-Approved
3HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.82)100%yesFDA-Approved
4c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.67)100%yesFDA-Approved
5AMFR
autocrine motility factor receptor
High (1.00)100%yesDiscovery
6PTPN13
protein tyrosine phosphatase non-receptor type 13
High (0.94)100%yesDiscovery
7MST1R
macrophage stimulating 1 receptor
High (0.67)100%yesFDA-Approved
8IRAK4
interleukin 1 receptor associated kinase 4
High (0.79)100%yesClinical
9FGFR1
fibroblast growth factor receptor 1
High (0.64)100%yesFDA-Approved
10NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.82)100%uncertainFDA-Approved
11KCNG1
potassium voltage-gated channel modifier subfamily G member 1
High (0.94)100%—FDA-Approved
12GPR139
G protein-coupled receptor 139
High (0.94)100%yesDiscovery
13EGFR
epidermal growth factor receptor
Medium (0.48)73%yesFDA-Approved
14FZD6
frizzled class receptor 6
High (0.92)100%yesDiscovery
15EPHB2
EPH receptor B2
High (0.73)100%uncertainFDA-Approved
16HRH4
histamine receptor H4
High (0.73)100%yesClinical
17CYSLTR2
cysteinyl leukotriene receptor 2
High (0.67)100%yesDiscovery
18IL1R2
interleukin 1 receptor type 2
High (0.64)100%yesDiscovery
19EEF2
eukaryotic translation elongation factor 2
High (1.00)100%—FDA-Approved
20AGTRAP
angiotensin II receptor associated protein
High (0.78)100%yesDiscovery
21FZD3
frizzled class receptor 3
High (0.79)100%yesDiscovery
22NOTCH3
notch receptor 3
High (0.64)91%yesClinical
23TREM1
triggering receptor expressed on myeloid cells 1
High (0.76)100%uncertainClinical
24MAOB
monoamine oxidase B
High (0.79)100%—FDA-Approved
25RNF43
ring finger protein 43
High (1.00)100%—Discovery

Internalizing receptors in endometrial cancer

Targets expressed in endometrial cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

S1PR1 · IGF1R · HER3 (ERBB3) · c-MET (MET) · AMFR · PTPN13 · MST1R · IRAK4 · FGFR1 · GPR139 · EGFR · FZD6

Endometrial Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in endometrial cancer. Clinical precedent lowers development risk but usually means more competition:

S1PR1 · IGF1R · HER3 (ERBB3) · c-MET (MET) · MST1R · IRAK4 · FGFR1 · NR3C2 · KCNG1 · EGFR · EPHB2 · HRH4

How these endometrial cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in endometrial cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank endometrial cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free endometrial cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist endometrial cancer targets for your program · 5 free analyses, no card Rank endometrial cancer targets free